MedPath

Spectral Lighting and Intestinal Failure

Not Applicable
Conditions
Intestinal Failure
Interventions
Other: Spectral Lighting
Registration Number
NCT06094504
Lead Sponsor
Children's Hospital Medical Center, Cincinnati
Brief Summary

The goal of this exploratory n-of-1-study is to compare markers of metabolism in infants with intestinal failure between two lighting environments. Investigators are seeking to learn whether supplementing the lighting environment of infants with intestinal failure with blue and violet wavelengths of light will allow more efficient utilization of the nutrition provided to participants by influencing hormones involved in regulation of growth and development as compared to a conventional lighting environment.

Pre-clinical studies suggest that violet and blue wavelengths of light are involved in molecular pathways that help regulate metabolic activity.

Detailed Description

Not available

Recruitment & Eligibility

Status
ENROLLING_BY_INVITATION
Sex
All
Target Recruitment
32
Inclusion Criteria
  • greater than or equal to 32 weeks post-menstrual age (PMA)
  • diagnosis or anticipated diagnosis of intestinal failure by qualified provider
  • have an anticipated hospital stay of at least 5 weeks following initiation of study participation
Exclusion Criteria
  • Infants with major congenital anomalies outside of the gastrointestinal tract
  • Infants with aneuploidy (having an abnormal amount of chromosomes)
  • Infants <32 weeks post-menstrual age (PMA)
  • Infants who are anticipated to require a major surgery after enrollment other than anastomosis.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Lighting cycling (Spectral vs Conventional)Spectral LightingA washout period of one week will commence the Monday after study subject enrollment, followed by four weeks of alternating periods of 3 days of daytime full spectrum lighting (FS) including violet and blue light wavelengths and 4 days of daytime conventional (CON) hospital lighting.
Primary Outcome Measures
NameTimeMethod
plasma protein concentration of insulinFor four weeks, once a week for each lighting condition and once a week during the predawn hours after each lighting condition, for a total of four samples per week.

Protein concentrations of plasma insulin as analyzed by SomaScan large scale proteomics assay will be compared among plasma samples taken in lighting conditions and between each lighting condition and dark.

plasma protein concentration of leptinFor four weeks, once a week for each lighting condition and once a week during the predawn hours after each lighting condition, for a total of four samples per week.

Protein concentrations of plasma insulin as analyzed by SomaScan large scale proteomics assay will be compared among plasma samples taken in lighting conditions and between each lighting condition and dark.

Secondary Outcome Measures
NameTimeMethod
CreatinineTypically collected twice-weekly for the duration of the participant's 4-week study timeline

creatinine concentration in mg/dL

AlbuminTypically collected twice-weekly for the duration of the participant's 4-week study timeline

albumin concentration in gm/dL

temperatureFor the duration of the participant's 4-week study timeline

body temperature as measured throughout the day, usually every 3-4 hrs

heart rateFor the duration of the participant's 4-week study timeline

heart rate throughout the day, as collected every 3-4 hrs

Phosphorus concentrationTypically collected twice-weekly for the duration of the participant's 4-week study timeline

concentration of Phosphorus in serum (mg/dL)

Magnesium concentrationTypically collected twice-weekly for the duration of the participant's 4-week study timeline

concentration of Magnesium in serum (mg/dL)

Calcium concentrationTypically collected twice-weekly for the duration of the participant's 4-week study timeline

concentration of Calcium in serum (mg/dL)

Sodium concentrationTypically collected twice-weekly for the duration of the participant's 4-week study timeline

concentration of Sodium in serum (mmol/L)

Potassium concentrationTypically collected twice-weekly for the duration of the participant's 4-week study timeline

concentration of Potassium in serum (mmol/L)

Chloride concentrationTypically collected twice-weekly for the duration of the participant's 4-week study timeline

concentration of Chloride in serum (mmol/L)

glucoseTypically collected twice-weekly for the duration of the participant's 4-week study timeline

glucose concentration in mg/dL

Blood Urea NitrogenTypically collected twice-weekly for the duration of the participant's 4-week study timeline

blood urea nitrogen concentration in mg/dL

Total protein levelTypically collected twice-weekly for the duration of the participant's 4-week study timeline

total protein concentration in gm/dL

Alanine Aminotransferase (ALT)Typically collected twice-weekly for the duration of the participant's 4-week study timeline

Alanine Aminotransferase concentration in unit/L

Aspartate Aminotransferase (AST)Typically collected twice-weekly for the duration of the participant's 4-week study timeline

Aspartate Aminotransferase (AST) concentration in unit/L

Alkaline Phosphatase (ALP)Typically collected twice-weekly for the duration of the participant's 4-week study timeline

Alkaline Phosphatase (ALP) concentration in unit/L

TriglycerideTypically collected twice-weekly for the duration of the participant's 4-week study timeline

Triglyceride concentration in mg/dL

Gamma Glutamyl Transferase (GGT)Typically collected twice-weekly for the duration of the participant's 4-week study timeline

Gamma Glutamyl Transferase (GGT) concentration in unit/L

Total BilirubinTypically collected twice-weekly for the duration of the participant's 4-week study timeline

Total Bilirubin concentration in mg/dL

Direct BilirubinTypically collected twice-weekly for the duration of the participant's 4-week study timeline

Direct Bilirubin concentration in mg/dL

Trial Locations

Locations (1)

Cincinnati Children's Hospital Medical Center

🇺🇸

Cincinnati, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath